Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-08-19 00:00:00 ET · period of report 2025-08-16 · accession 0000950170-25-110274 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-08-19 | 2025-08-16 | BBIO | Trimarchi Thomas | Pres, CFO | F - Tax | $51.32 | -21.3K | 480.7K | -4% | -$1.09M |
| MT | 2025-08-19 | 2025-08-18 | BBIO | Trimarchi Thomas | Pres, CFO | S - Sale | $50.23 | -17.4K | 463.3K | -4% | -$871.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-16 | F | D | 21,317 | $51.32 | 480,671 | D | — | — | (F1) Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 38,547 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. |
| 2 | Common | Common Stock | 2025-08-18 | S | D | 15,380 | $50.14 | 465,291 | D | — | — | (F3) Represents the weighted average sale price of the shares sold from $49.76 to $50.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-08-18 | S | D | 1,973 | $50.94 | 463,318 | D | — | — | (F4) Represents the weighted average sale price of the shares sold from $50.83 to $50.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |